LOGIN  |  REGISTER
Terns Pharmaceuticals

electroCore to Participate at the Needham Virtual Healthcare Conference

April 01, 2025 | Last Trade: US$4.74 0.28 -5.58

ROCKAWAY, N.J., April 01, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that management will participate at the Needham Virtual Healthcare Conference taking place virtually on April 10, 2025.

Dan Goldberger, CEO and Joshua Lev, Chief Financial Officer, will host a group presentation at 2:15 p.m. ET and participate in one-on-one meetings throughout the day.

DATE: April 10, 2025
TIME: 2:15 p.m. ET
WEBCAST: electroCore Group Presentation

A live audio webcast and replay of the presentation will be available using the above dedicated link. Investors attending the conference who are interested in scheduling a meeting with management can do so by contacting their Needham representative, or by emailing FNK IR at This email address is being protected from spambots. You need JavaScript enabled to view it. for more information.

About electroCore, Inc.

electroCore, Inc. is a commercial stage bioelectronic medicine and wellness company dedicated to improving health through its non-invasive vagus nerve stimulation (“nVNS”) technology platform. Our focus is the commercialization of medical devices for the management and treatment of certain medical conditions and consumer product offerings utilizing nVNS to promote general wellbeing and human performance in the United States and select overseas markets.

For more information, visit www.electrocore.com.

Contact

ECOR Investor Relations
(973) 302-9253
This email address is being protected from spambots. You need JavaScript enabled to view it.

Viking Therapeutics

Stock Quote

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page